Delivery Order SPE2DB20D3505-SPE2DB25FU5M3
Award Date 5/6/25
Potential Completion Date 5/7/25
Potential Value $9.6K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $117,847.83 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of September 2, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly prescribed for conditions...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a $7,247.34 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various allergic and inflammatory conditions, representing a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $40,361.19. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively evaluated. The contract represents a continuation of the company's pharmaceutical supply role supporting federal medical procurement needs, with performance to be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectables on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being fulfilled from AmerisourceBergen's place of business in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a $59,468.29 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside competitive award is scheduled for completion by August 28, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis and other inflammatory conditions, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $33,274.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and does not include a set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication...
- The Defense Logistics Agency awarded a $5,642.53 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml). This is a firm fixed price, non-set-aside contract with an ultimate completion date of May 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis,...
- The Defense Logistics Agency awarded a delivery order valued at $91,743.02 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...